



PATENT CASE: DX01136K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Smith & Zlotnik

Examiner: Christopher J. Nichols

For: Uses of Mammalian Genes and
Related Reagents

Group Art Unit: 1647

Serial No.: 09/920,318

Filing Date: July 31, 2001

RECEIVED

JUN 02 2003

TECH CENTER 1600/2900

May 27, 2003

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

This is in response to the Office Action (Paper #13; Confirmation No. 5031) dated February 27, 2003, in the above-identified application, for which a response is due May 27, 2003.

PLEASE AMEND THE APPLICATION AS FOLLOWS:

SEQUENCE LISTING

Please incorporate the Sequence Listing as attached herein.

IN THE SPECIFICATION

On page 19, lines 8-23, please replace the current paragraph with the following:

Ten ng of cDNA/reaction was analyzed for expression of selected chemokines, chemokine receptors, and ubiquitin on a GeneAmp 5700 Sequence Detector (PE Applied Biosystems) in a 25 μ L reaction. Expression of chemokines and chemokine receptors was detected using primers and probe (PE Applied Biosystems) with TaqMan Universal Master Mix (PE Applied Biosystems) or primers alone and SYBR Green PCR Master Mix (PE Applied Biosystems). TaqMan reagents to detect expression of given chemokines or their receptors were extensively tested to verify that they only recognized the appropriate target sequence and not closely related family members. Ubiquitin was detected using 200 nM primers (F: CACTTGGTCCTGCGCTTGA (SEQ ID NO: 1); R: CAATTGGGAATGCAACAACCTTTAT (SEQ ID NO: 2)) with SYBR Green PCR Mater Mix. The data was analyzed to calculate a cycle threshold value (Ct) for each sample with GeneAmp 5700 SDS Software (PE Applied Biosystems). The relative level of CCL18 mRNA in the tissue using the following formula: $1.8(Ct \text{ of ubiquitin} - Ct \text{ of gene of interest})10,000$ for each sample. Mean and standard error were calculated for each group.